Human hepatocyte metabolism of novel synthetic cannabinoids MN-18 and its 5-fluoro analog 5F-MN-18
PublisherAmerican Association for Clinical Chemistry Inc.
MetadataShow full item record
AbstractBACKGROUND: In 2014, 2 novel synthetic cannabinoids, MN-18 and its 5-fluoro analog, 5F-MN-18, were first identified in an ongoing survey of novel psychoactive substances in Japan. In vitro pharmacological assays revealed that MN-18 and 5F-MN-18 displayed high binding affinities to human CB1 and CB2 receptors, with Ki being 1.65- 3.86 nmol/L. MN-18 and 5F-MN-18 were scheduled in Japan and some other countries in 2014. Despite increasing prevalence, no human metabolism data are currently available, making it challenging for forensic laboratories to confirm intake of MN-18 or 5F-MN-18. METHODS: We incubated 10 ?mol/L of MN-18 and 5F-MN-18 in human hepatocytes for 3 h and analyzed the samples on a TripleTOF 5600+ high-resolution mass spectrometer to identify appropriate marker metabolites. Data were acquired via full scan and informationdependent acquisition-triggered product ion scans with mass defect filter. RESULTS: In total, 13 MN-18 metabolites were detected, with the top 3 abundant metabolites being 1-pentyl-1Hindazole- 3-carboxylic acid, pentyl-carbonylated MN-18, and naphthalene-hydroxylated MN-18. For 5F-MN-18, 20 metabolites were observed, with the top 3 abundant metabolites being 5'-OH-MN-18, MN-18 pentanoic acid, and 1-(5-fluoropentyl)-1H-indazole-3-carboxylic acid. CONCLUSIONS: We have characterized MN-18 and 5FMN- 18 metabolism with human hepatocytes and highresolution mass spectrometry, and we recommend characteristic major metabolites for clinical and forensic laboratories to identify MN-18 and 5F-MN-18 intake and link observed adverse events to these novel synthetic cannabinoids.
Keyword1-Naphthylamine--analogs & derivatives
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85032978389&doi=10.1373%2fclinchem.2017.277152&partnerID=40&md5=eb7b35660f8aeb8e06de5123d06380c3; http://hdl.handle.net/10713/11120
- Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry.
- Authors: Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA
- Issue date: 2014 Feb
- Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry.
- Authors: Andersson M, Diao X, Wohlfarth A, Scheidweiler KB, Huestis MA
- Issue date: 2016 Apr 30
- Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry.
- Authors: Carlier J, Diao X, Scheidweiler KB, Huestis MA
- Issue date: 2017 May
- High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes.
- Authors: Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA
- Issue date: 2016 Jan
- Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.
- Authors: Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA
- Issue date: 2015 May